2型糖尿病とメタボリックシンドロームに対する新薬標的

D E Moller¹

¹Departments of Molecular Endocrinology and Metabolic Disorders, Merck Research Laboratories, Rahway, New Jersey 07065, USA.

Nature

|December 14, 2001

まとめ

メタボリックシンドロームの世界的な増加は,2型糖尿病の流行を助長しています. 新しい治療法は,インスリン分泌の低下や脂質毒性などの重要なメカニズムを標的とし,効果的な治療法への希望を提供します.

科学分野:

内分泌学と新陳代謝について
分子医学は分子医学である.
薬理学薬理学とは

背景:

肥満,インスリン抵抗性,脂質不全によって特徴づけられる代謝症候群は,2型糖尿病の世界的な流行を引き起こしています.
現在の2型糖尿病の治療には,疾患の病原性の理解が不完全であるため,特定の分子標的が欠けていることが多い.

研究の目的:

2型糖尿病の新興分子薬標的を強調する.
病気のメカニズムの理解における最近の進歩を参考に,新たな治療戦略について議論する.

主な方法:

メタボリックシンドロームと2型糖尿病の病原性に関する現在の知識のレビュー.
病気の進行に関与する主要な分子標的の特定と議論.
動物モデルにおける遺伝子工学による目標の検証と,ヒト/動物に関する予備的な研究.

主要な成果:

新興の研究は,グルコース刺激によるインスリン分泌の障害を重要な要因として特定しています.
脂質毒性は,肝臓および筋肉のインスリン抵抗性への重要な要因として認識されています.
いくつかの新しい分子標的が,臨床前および臨床初期で特定され,検証されています.

結論:

インスリン抵抗性およびインスリン分泌障害の分子基礎を理解することは,効果的な2型糖尿病治療の開発に不可欠です.
脂質毒性およびインスリン分泌メカニズムによる新薬標的は有望である.
ターゲティングセラピーは,代謝症候群と2型糖尿病の流行の管理における重要な進歩を表しています.

さらに関連する動画

08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

関連する概念動画

01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

関連する実験動画